Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
Jones, R Vuky, J Elliott, Tony Mead, G Arranz, J Chester, J Chowdhury, S Dudek, A Müller-Mattheis, V Grimm, M
Jones, R
Vuky, J
Elliott, Tony
Mead, G
Arranz, J
Chester, J
Chowdhury, S
Dudek, A
Müller-Mattheis, V
Grimm, M
Citations
Altmetric:
Abstract
AZD4877 is a potent inhibitor of the mitotic spindle kinesin, Eg5. Early-phase clinical studies in a broad range of cancers showed that AZD4877 is well tolerated. This Phase II study evaluated the efficacy, safety and pharmacokinetics (Cmax) of AZD4877 in patients with previously treated advanced urothelial cancer (ClinicalTrials.gov identifier NCT00661609).
Description
Date
2013-08
Publisher
Collections
Keywords
Type
Article
Citation
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. 2013, 31 (4):1001-7 Invest New Drugs